Related Experiment Video
Updated: Jul 4, 2026

06:18
An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
Non-estrogen-based treatments for menopausal symptoms
1, Joan Pitkin, Margaret C P Rees
1University of Oxford, , Oxford OX3 9DU, UK.
Menopause International
|June 4, 2008
Summary
This guidance reviews non-estrogen treatments for menopausal symptoms like hot flushes and urogenital atrophy. It emphasizes personalized, up-to-date strategies, especially for women with estrogen-dependent conditions.
Area of Science:
- Reproductive Medicine
- Gynecology
- Endocrinology
Background:
- The British Menopause Society Council provides authoritative reviews on postreproductive health.
- Menopausal symptoms significantly impact women's quality of life, including hot flushes, urogenital atrophy, and decreased libido.
- Estrogen-dependent conditions, such as breast cancer, necessitate alternative treatment approaches.
Purpose of the Study:
- To review and present up-to-date information on non-estrogen-based treatments for menopausal symptoms.
- To guide health professionals in advising women on managing postreproductive health issues.
- To highlight the importance of individualized treatment plans tailored to women's specific needs.
Main Methods:
- Review of current literature and clinical guidelines on non-hormonal menopausal symptom management.
- Focus on treatments applicable to women with contraindications for estrogen therapy.
- Consideration of symptom-specific and patient-specific factors in treatment selection.
Main Results:
- Non-estrogen-based therapies offer effective management options for common menopausal symptoms.
- These strategies are particularly crucial for women with a history of or predisposition to estrogen-sensitive cancers.
- Personalized treatment selection ensures optimal outcomes and patient adherence.
Conclusions:
- Health professionals should utilize evidence-based, non-estrogen treatments for menopausal symptom management.
- Tailoring treatment to individual needs and medical history is paramount.
- Non-hormonal options provide a safe and effective alternative for many women, including those with estrogen-dependent diseases.
Related Concept Videos
Menopause
Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...
Hormonal Regulation of the Menstrual Cycle
The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH release.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH release.
Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Disorders of the Female Reproductive System
The female reproductive system can be affected by several disorders, including Premenstrual Syndrome (PMS), Premenstrual Dysphoric Disorder (PMDD), endometriosis, and various forms of cancer. PMS and PMDD are cyclical conditions that cause physical and emotional distress, with symptoms that include edema, mood swings, and food cravings. PMDD is a more severe form of PMS characterized by increased symptom severity that peaks during the luteal phase and tends to improve or resolve shortly after...
Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
The Menstrual Cycle
The menstrual cycle is a recurrent sequence of changes in the uterine endometrium, specifically its functional layer, the stratum functionalis. This cycle prepares the uterus for potential pregnancy. This cycle typically spans 21–35 days, averaging 28 days, and aligns with the ovarian cycle, regulated by fluctuating levels of ovarian hormones, primarily estrogen and progesterone.
The menstrual phase occurs from days 1 to 5 and involves the shedding of the stratum functionalis, as a uterine...
The menstrual phase occurs from days 1 to 5 and involves the shedding of the stratum functionalis, as a uterine...
